Richard L. Wang Named Chief Executive Officer of Fosun Kite Biotechnology Co., Ltd., a Joint Venture to Lead Development of Axicabtagene Ciloleucel and Other Engineered T-Cell Therapies for Treatment of Cancers in China Kite Pharma, Inc., today announced that Richard L. Wang, Ph.D. will be appointed Chief Executive Officer of Fosun Kite Biotechnology Co., Ltd, the company’s 50/50 owned joint venture in China with Shanghai Fosun Pharmaceutical Co., Ltd. .The companies announced the formation of the joint venture in early 2017 to develop, manufacture and commercialize autologous T-cell therapies to treat cancer in China, including Kite’s lead cell therapy product candidate, axicabtagene ciloleucel.
Category: University of Maryland Baltimore
UMB and Nonprofit Guidewell Financial Solutions Partner on NCRG…
… for Treatment or ‘SBIRT’ to assess for at-risk alcohol use, drug use, and tobacco use. However, gambling is not a health-related behavior and prevalence in the general population is relatively low. Nonprofit consumer credit counseling agencies like …
Focusing on Pharmacists
… pharmacy department to provide cooking classes for diabetic patients or different services that work around the health and wellness aspect of nutrition.” In this case, the supermarket works with a nearby pain-management clinic. Others may serve a …